Yong Zhu

OverviewAI-generated summary

Yong Zhu's research focuses on molecular epidemiology, with a particular emphasis on identifying biomarkers associated with cancer risk, progression, and survival, and exploring their translational applications. His laboratory investigates the influence of circadian factors, including night shift work and genetic variations in circadian genes, on the development of cancer. This work also extends to translational research concerning small noncoding RNAs.

Dr. Zhu's published work includes studies on the epigenetic modifications associated with valerian and valeric acid's effects on breast cancer cells, the selective destabilization of oncogenic fusion proteins by hyperthermia, and the association of frailty with cardiovascular disease and type 2 diabetes risk in cancer survivors. Other publications address the role of ZNF117 in glioblastoma stem cell differentiation, N-nitrosamine-mediated downregulation of LncRNA-UCA1 in esophageal squamous cell carcinogenesis, and an analysis of ubiquitination modifications in breast cancer. He also has experience with systematic reviews and meta-analyses, as demonstrated by a publication on hip versus knee strengthening for patellofemoral pain syndrome.

He is recognized as a high-impact researcher, evidenced by his h-index of 41 and over 5,300 citations across 135 publications. Dr. Zhu has received federal funding, including a $411,876 grant from the NIH/National Cancer Institute to explore piRNAs as potential biomarkers for early ovarian cancer detection, serving as Principal Investigator on this award. He leads a research group and maintains an active laboratory website.

Metrics

• h-index: 41
• Publications: 135
• Citations: 5,374